We recently compiled a list of 11 Best Future Stocks to Buy Now. Arrowhead Pharmaceuticals, Inc. stands seventh on our list.

Monday announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ:SRPT). The milestone ...

US RNA interference (RNAi)specialist Arrowhead Pharmaceuticals (Nasdaq: ARWR) today announced that its majority-owned subsidiary Visirna Therapeutics has signed an asset purchase agreement with France ...

Arrowhead Pharmaceuticals strikes a $130M+ deal with Sanofi for plozasiran in Greater China, targeting high triglyceride ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

When Pasadena-based Arrowhead Pharmaceuticals Inc. signed a huge licensing and collaboration deal with Cambridge, ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to ...

Arrowhead Pharmaceuticals said it earned a $100 million milestone payment from Sarepta Therapeutics. The milestone was triggered when Arrowhead reached the first of two prespecified enrollment targets ...

Arrowhead said it has met both of these conditions in a July 28 release and now expects to receive the $100 million within 60 days. The company also said it plans on reaching the second enrollment ...

Wall Street had a slew of upgrades and downgrades from analysts. Here are some of the major calls for the week: J.P. Morgan ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100-million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). This morning’s news release reported that ...